Bendamustine

Bendamustine (SDX-105 free base), a purine analogue, is a DNA cross-linking agent. Bendamustine activates DNA-damage stress response and apoptosis. Bendamustine has potent alkylating, anticancer and antimetabolite properties[1].

Product Specifications

CAS Number

[16506-27-7]

Product Name Alternative

SDX-105 (free base)

UNSPSC

12352005

Hazard Statement

H301, H311, H331, H341

Target

Apoptosis; DNA Alkylator/Crosslinker

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Bendamustine.html

Purity

98.0

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)CCCC1=NC2=CC(N(CCCl)CCCl)=CC=C2N1C

Molecular Formula

C16H21Cl2N3O2

Molecular Weight

358.26

Precautions

H301, H311, H331, H341

References & Citations

[1]Leoni LM, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008 Jan 1;14 (1) :309-17.|[2]Cives M, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013 May;25 (5) :1108-17.|[3]Ackler S, et al. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo. Br J Pharmacol. 2012 Oct;167 (4) :881-91.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C (Powder, protect from light)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Leukemia. 2023 Nov;37 (11) :2221-2230.|Cell Rep Med. 2025 Apr 2:102053.|J Biomed Res. 2017 0 (0) : 1-12.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Patent. US20160222465A1.